185 related articles for article (PubMed ID: 33151095)
1. Li-Fraumeni Syndrome and Whole-Body MRI Screening: Screening Guidelines, Imaging Features, and Impact on Patient Management.
Consul N; Amini B; Ibarra-Rovira JJ; Blair KJ; Moseley TW; Taher A; Shah KB; Elsayes KM
AJR Am J Roentgenol; 2021 Jan; 216(1):252-263. PubMed ID: 33151095
[TBL] [Abstract][Full Text] [Related]
2. Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients.
Paixão D; Guimarães MD; de Andrade KC; Nóbrega AF; Chojniak R; Achatz MI
Cancer Imaging; 2018 Aug; 18(1):27. PubMed ID: 30107858
[TBL] [Abstract][Full Text] [Related]
3. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
4. Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
Dixon-Zegeye M; Shaw R; Collins L; Perez-Smith K; Ooms A; Qiao M; Pantziarka P; Izatt L; Tischkowitz M; Harrison RE; George A; Woodward ER; Lord S; Hawkes L; Evans DG; Franklin J; Hanson H; Blagden SP
Trials; 2024 Feb; 25(1):103. PubMed ID: 38308321
[TBL] [Abstract][Full Text] [Related]
5. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study.
O'Neill AF; Voss SD; Jagannathan JP; Kamihara J; Nibecker C; Itriago-Araujo E; Masciari S; Parker E; Barreto M; London WB; Garber JE; Diller L
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29077256
[TBL] [Abstract][Full Text] [Related]
6. Rates of Intervention and Cancer Detection on Initial versus Subsequent Whole-body MRI Screening in Li-Fraumeni Syndrome.
Kagami LAT; Du YK; Fernandes CJ; Le AN; Good M; Duvall MM; Baldino SE; Powers J; Zelley K; States LJ; Mathew MC; Katona BW; MacFarland SP; Maxwell KN
Cancer Prev Res (Phila); 2023 Sep; 16(9):507-512. PubMed ID: 37428016
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
[TBL] [Abstract][Full Text] [Related]
8. [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
Frebourg T; Abel A; Bonaiti-Pellie C; Brugières L; Berthet P; Bressac-de Paillerets B; Chevrier A; Chompret A; Cohen-Haguenauer O; Delattre O; Feingold J; Feunteun J; Frappaz D; Fricker JP; Gesta P; Jonveaux P; Kalifa C; Lasset C; Leheup B; Limacher JM; Longy M; Nogues C; Oppenheim D; Sommelet D; Soubrier F; Stoll C; Stoppa-Lyonnet D; Tristant H
Bull Cancer; 2001 Jun; 88(6):581-7. PubMed ID: 11459705
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of imaging approaches for early tumor detection in children with Li-Fraumeni syndrome.
Tewattanarat N; Junhasavasdikul T; Panwar S; Joshi SD; Abadeh A; Greer MLC; Goldenberg A; Zheng G; Villani A; Malkin D; Doria AS
Pediatr Radiol; 2022 Jun; 52(7):1283-1295. PubMed ID: 35391548
[TBL] [Abstract][Full Text] [Related]
10. [Li-Fraumeni syndrome].
Keymling M; Schlemmer HP; Kratz C; Pfeil A; Bickelhaupt S; Alsady TM; Renz DM
Radiologie (Heidelb); 2022 Dec; 62(12):1026-1032. PubMed ID: 36166074
[TBL] [Abstract][Full Text] [Related]
11. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
[TBL] [Abstract][Full Text] [Related]
12. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
13. [Li-Fraumeni syndrome in a patient with multiple anaplastic oligodendrogliomas of the brain (a case report and literature review)].
Potapov AA; Abdilatipov AA; Okhlopkov VA; Gavrilov AG; Zakharova NE; Goryaynov SA; Kobyakov GL; Absalyamova OV; Kravchuk AD; Kulikov AS; Shugay SV; Nikitin PV; Batalov AI; Shelygin YA; Lyubchenko LN; Aliev MD; Spallone A
Zh Vopr Neirokhir Im N N Burdenko; 2018; 82(4):87-96. PubMed ID: 30137042
[TBL] [Abstract][Full Text] [Related]
14. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
Masciari S; Van den Abbeele AD; Diller LR; Rastarhuyeva I; Yap J; Schneider K; Digianni L; Li FP; Fraumeni JF; Syngal S; Garber JE
JAMA; 2008 Mar; 299(11):1315-9. PubMed ID: 18349092
[TBL] [Abstract][Full Text] [Related]
15. [Whole-body MRI in cancer predisposition syndromes].
Herrmann J; Esser M; Brecht I; Tsiflikas I; Schäfer JF
Radiologie (Heidelb); 2022 Dec; 62(12):1017-1025. PubMed ID: 36098807
[TBL] [Abstract][Full Text] [Related]
16. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition.
Valdez JM; Nichols KE; Kesserwan C
Br J Haematol; 2017 Feb; 176(4):539-552. PubMed ID: 27984644
[TBL] [Abstract][Full Text] [Related]
17. [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI].
Foretová L; Stěrba J; Opletal P; Mach V; Lisý J; Petráková K; Palácová M; Navrátilová M; Gaillyová R; Puchmajerová A; Křepelová A; Macháčková E
Klin Onkol; 2012; 25 Suppl():S49-54. PubMed ID: 22920207
[TBL] [Abstract][Full Text] [Related]
18. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
[TBL] [Abstract][Full Text] [Related]
19. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
20. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
